Chief Executive Officer, Cell and Gene Therapy Catapult
Matthew Durdy is Chief Executive of the Cell and Gene Therapy Catapult, having been part of the founding team in 2012. Prior to 2020, he was Chief Business Officer and was responsible for strategy, communications, marketing, and business development. He is credited with leading the design and implementation of the commercial model for the highly successful Cell and Gene Therapy Catapult manufacturing centre and being a global champion for the early integration of healthcare economics and reimbursement expertise into decision-making and clinical product design.
He began his career in international investment banking and venture capital, and has successfully invested in and managed a number of biotechnology SMEs and regional operations of multinational organisations. He has an MA from the University of Oxford in Pure and Applied Biology, an MBA from the University of Chicago, and is a Fellow of the Chartered Institute for Securities and Investment. He is also Vice Chair of the Board of Trustees of the charity Parkinson’s UK.
Stevenage Bioscience Catalyst30 November 2023